On ECHEMI
Home > Drugs > Posterior pituitary injection

Posterior pituitary injection

Function and Efficacy

Posterior pituitary injection has a strong contraction effect on smooth muscle, especially on blood vessels and the base of the uterus. Depending on the dosage, it can cause rhythmic contraction of the uterus to tonic contraction. It can also increase the tension of the intestines and bladder to cause them to contract. In addition, the posterior pituitary can also inhibit urination.

Ingredients

The main ingredients of this product are: posterior pituitary

Appearance

This product is a colorless, clear or almost clear liquid.

Indication

It is used for pulmonary and bronchial bleeding (such as hemoptysis) and digestive tract bleeding (hematemesis, blood in the stool), and is suitable for inducing labor in obstetrics, contracting the uterus and stopping bleeding after delivery. It is also effective for intestinal paralysis after abdominal surgery. This product also has the effect of reducing urine output in diabetes insipidus.

Usage and Dosage

Intramuscular, subcutaneous injection or intravenous drip after dilution. Intravenous drip for induction or acceleration of labor: 1. 2.5-5 units at a time, diluted with sodium chloride injection to contain 0.01 unit per 1 ml. At the beginning of intravenous drip, no more than 0.001-0.002 units per minute, increase by 0.001-0.002 units every 15-30 minutes until uterine contractions are similar to those during normal delivery, and the fastest is no more than 0.02 units per minute, usually 0.002-0.005 units per minute. Control postpartum hemorrhage with intravenous drip of 0.02-0.04 units per minute, and 5-10 units can be injected intramuscularly after the placenta is expelled. Respiratory or digestive tract bleeding: 6-12 units at a time. Postpartum uterine bleeding: 3-6 units at a time.

Adverse Reactions

Not yet clear

Precautions

This product is not suitable for patients with nephritis, myocarditis, vascular sclerosis, narrow pelvis, twins, polyhydramnios, excessive uterine expansion, etc. It is also not suitable for patients with cervical dilation that has not yet fully expanded. It should be used with caution in patients with hypertension and coronary artery disease.

Special Population Medication

Precautions during pregnancy and lactation: This product is not suitable for patients with narrow pelvis, twins, polyhydramnios, excessive uterine distension, etc. It is also not suitable for use when the cervix has not yet fully dilated.

Drug Interactions

1. When cyclopropane and other hydrocarbons are inhaled for general anesthesia, the use of oxytocin can cause hypotension, sinus bradycardia or (and) atrioventricular dysrhythmia in the parturient. When enflurane concentration is >1.5% and halothane concentration is >1.0% during inhalation general anesthesia, the effect of the uterus on oxytocin is weakened. Enflurane concentration >3.0% can eliminate the reaction and may cause uterine bleeding. 2. When other uterotonic drugs are used simultaneously with oxytocin, the uterine tension may be too high, resulting in uterine rupture or (and) cervical tear.

Storage

Seal tightly and store in a cool, dark place.

Packaging Specification

0.5ml: 3 units

Manufacturer

Chengdu Hepatunn Pharmaceutical Co., Ltd.

  • Founded in:

    2010-12-07
  • Address:

    No. 222, Liutai Avenue, Chengdu Cross-Strait Science and Technology Industrial Development Park, Wenjiang District, Chengdu
  • Tax NO.:

    91510115564494843U
  • Registered Funds:

    40 million yuan
  • Website:

  • Email:

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.